Breaking News
December 10, 2018 - UC San Diego professor receives NCI Outstanding Investigator Award for cancer research
December 10, 2018 - Study evaluates placental mesenchymal stem cell sheets for myocardial repair and regeneration
December 10, 2018 - Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis
December 10, 2018 - Study clarifies ApoE4’s role in dementia
December 10, 2018 - Neuronal activity in the brain allows prediction of risky or safe decisions
December 10, 2018 - FDA Alerts Health Care Professionals and Patients Not to Use Drug Products Intended to be Sterile from Promise Pharmacy
December 10, 2018 - Improving dementia care and treatment saves thousands of pounds in care homes
December 10, 2018 - Heroin-assisted treatment can offer benefits, reduce harms
December 10, 2018 - People covered by Michigan’s expanded Medicaid program report improvements in health, finds study
December 10, 2018 - Hazelnuts improve micronutrient levels in older adults
December 9, 2018 - History of Partner Violence Tied to Menopause Symptoms
December 9, 2018 - Clean Up Safely After a Disaster|Natural Disasters and Severe Weather
December 9, 2018 - Drug wholesalers drove fentanyl’s deadly rise, report concludes
December 9, 2018 - Deprescribing could help manage polypharmacy in older adults
December 9, 2018 - Retraction of article “Joy of cooking too much” from journal
December 9, 2018 - FDA Warns of Rare Stroke Risk With MS Drug Lemtrada (Alemtuzumab)
December 9, 2018 - Feds say heroin, fentanyl remain biggest drug threat to US
December 9, 2018 - Eliminating microglia can reverse some aspects of stress sensitization, study shows
December 9, 2018 - New genetic insight could help treat rare debilitating heart and lung condition
December 9, 2018 - MiRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides
December 9, 2018 - Work with your doctor to weigh pros, cons of treatment options for hyperthyroidism
December 9, 2018 - CWRU researcher secures $14.6 million funding for genetic study into Alzheimer’s disease
December 9, 2018 - High intensity statin treatment and adherence could save more lives
December 9, 2018 - Surgery patients use only 1/4 of prescribed opioids, and prescription size matters
December 9, 2018 - AXT offers Phi Optics upgrade to QPI systems for inverted light microscopes
December 9, 2018 - New booklet could help improve conditions of young pupils with albinism
December 9, 2018 - Few Physicians Work in Practices That Use Telemedicine
December 9, 2018 - Older Adults and Oral Health
December 9, 2018 - Health utility values improve after septorhinoplasty
December 9, 2018 - New EU-funded project provides insight into how the brain develops
December 9, 2018 - Expanded use of tele-emergency services can help strengthen rural hospitals
December 9, 2018 - Infections in the Young May Be Tied to Risk for Mental Illness: Study
December 9, 2018 - Profile: Native Hawaiians and Pacific Islanders
December 9, 2018 - Snoring poses greater cardiac risk to women
December 9, 2018 - Researcher takes further steps in understanding how and why cute aggression occurs
December 9, 2018 - Researchers create new light-activated tools for controlling neurons
December 9, 2018 - Spinal cord injury disrupts the body’s internal clock, study shows
December 9, 2018 - Babies recognize nested structures similar to our grammar
December 9, 2018 - UT Austin researcher receives $2.5 million CZI grant for neurodegenerative disease research
December 9, 2018 - Sleep problems found to be prevalent and increasing among college students
December 9, 2018 - Study reveals why some children are susceptible to the effects of maltreatment
December 9, 2018 - Study investigates influence of different opioids on driving performance
December 9, 2018 - Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
December 9, 2018 - Eliminating microglia prevents heightened immune sensitivity after stress
December 9, 2018 - Boys with social difficulties are at greatest risk of early substance use
December 9, 2018 - ‘Wrong’ connective tissue cells linked to worse prognosis in breast cancer patients
December 8, 2018 - Chronic, refractory schizophrenia patients benefit from targeted cognitive training
December 8, 2018 - Advertising in kids’ apps more prevalent than parents may realize
December 8, 2018 - New way to trace the transmission histories of rare genetic diseases
December 8, 2018 - ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma
December 8, 2018 - Results of pediatric genomic epilepsy tests often reclassified
December 8, 2018 - New way of controlling HIV latency to completely eradicate the virus
December 8, 2018 - Phasefocus to showcase the Livecyte 2 at ASCB
December 8, 2018 - KHN’s ‘What the Health?’ Is health spending the next big political issue?
December 8, 2018 - Mussels take in microplastic pollution fibers and flush most of them out again
December 8, 2018 - AHA: How to Stop Smoking … for Good
December 8, 2018 - Scientists overturn odds to make Parkinson’s discovery
December 8, 2018 - Health benefits of producing marula vinegar
December 8, 2018 - Failure of critical cellular energy sensor responsible for CKD progression, study finds
December 8, 2018 - Ethnicity can be reliable indicator of gut microbiota diversity
December 8, 2018 - Safe Sleep for Baby | NIH News in Health
December 8, 2018 - Study looks at ways technology can support nutritional needs of Parkinson’s patients
December 8, 2018 - Infant milk allergy is being overdiagnosed say experts
December 8, 2018 - Graphene may one day be used to test for ALS
December 8, 2018 - Houston Methodist launches real-time website to track flu cases
December 8, 2018 - RedHill Announces Positive Top-Line Results from Confirmatory Phase 3 Study with Talicia for H. pylori Infection
December 8, 2018 - A way to measure obesity and health beyond BMI
December 8, 2018 - New diagnostic tools may help identify breast cancer patients who could benefit from targeted therapies
December 8, 2018 - Duke-NUS researchers highlight possible role of bioaerosol sampling in pandemic surveillance
December 8, 2018 - Study quantifies links between alcohol, drug use and violent deaths
December 8, 2018 - Mothers’ stress levels at conception linked to child’s response to life challenges at age 11
December 8, 2018 - MIT researchers develop antimicrobial peptides from South American wasp’s venom
December 8, 2018 - Obesity prevention among low-income, diverse preschool-aged children and parents
December 8, 2018 - Mount Sinai researcher awarded $2.5 million to advance understanding of neurodegenerative diseases
December 8, 2018 - CZI announces funding for open-source software efforts to improve image analysis in biomedicine
December 8, 2018 - New book encompasses the vast history of reproduction
December 8, 2018 - Low-income women in Texas are not receiving contraception after childbirth, study shows
December 8, 2018 - Study expands knowledge about sexuality and gender gaps in political attitudes
December 8, 2018 - Drug reduces hot flash frequency, improves quality of life in breast cancer survivors
December 8, 2018 - Imaging, Biopsy Often Still Needed After Mastectomy
The ADHD brain retrained

The ADHD brain retrained

image_pdfDownload PDFimage_print
The ADHD brain retrained
Credit: rozbeh, Shutterstock

The cost of attention deficit hyperactivity disorder (ADHD) can be as high as EUR 7,000 per patient per year in the United Kingdom and some 4 million children suffer from the disorder in Europe. NEWROFEED has developed a personalised, drug-free treatment for home use based on neurofeedback.

ADHD is a chronic debilitating disorder usually diagnosed during childhood. It negatively impacts many aspects of young patients’ lives including academic achievements, social skills and perception of self-worth. It’s not surprising then that this can lead to strained parent-child relationships.

The most common treatment for ADHD is a form of psychoactive medication, which in many cases is methylphenidate (MPH), an amphetamine. While these drugs do have a positive impact, leading to short-term adaptation of the child’s behaviour, they have significant side effects, impacting sleep, appetite and sometimes the personality of the child through affective blunting (reduction in emotional response), and reduced creativity.

Personalised neurofeedback therapy

The EU-funded NEWROFEED project has developed a “safe alternative with a superior benefit / risk ratio for patients, who are not willing to take drugs due to severe adverse events,” informs Dr. Michel du Peloux, project coordinator and chief executive officer of Mensia Technologies who developed the device. NEWROFEED implemented the non-inferiority study to demonstrate that the medical device Mensia Koala would be non-inferior to the reference drug treating ADHD for children aged 7 to 13 years old.

As du Peloux explains, “There is a need for innovative, drug-free treatments for ADHD. We believe there is an alternative: neurofeedback, a methodology to ‘rewire’ the brain that was conceptualised in France as early as the 1960s and later developed in the US from the 1960s onwards.” The technique is self-paced and uses electroencephalography (EEG) signals from the brain to help the patient train brain functions and normalise activity to a healthy range.

Robust and user-friendly enough for home use

NEWROFEED took advantage of advances in research for the deployment of neurofeedback as a large-scale treatment for ADHD. This has helped eliminate problems with heterogeneous methodologies and technical implementations in existing trials as well as lack of standardised implementation for automated neurofeedback delivery. Recent breakthroughs in real-time software and hardware design and function have also enabled the fully automated device to be user-friendly and robust enough after minimal training for home use.

“We now have gold standard European clinical proof that Mensia Kola is an effective and safe therapy for sub groups of ADHD patients,” affirms Dr. du Peloux “with the outstanding benefit of ‘at home’ brain training.” The personalised neurofeedback protocols can be delivered on the affordable, user-friendly device to optimise training at home under remote medical supervision. The final release of SMR neuromarkers will supply evidence of this.

Technical and organisational challenges

The amplifier of the system exhibited classical defaults in the prototype. “However, more resources and formation of a specific task force allowed us to gain high level expected quality for our exclusive device after some months of testing,” explains Dr. du Peloux.

For delay challenges, there were heavy constraints on fostering rapid enrolment in five countries. However, Dr. du Peloux has over 30 years’ experience in management positions in the pharmaceutical, medical device and healthcare world. “My expertise and the whole team’s efforts across five countries served to overcome problems with enrolment and resulted in better communication by establishing new selection centre in countries,” he emphasises.

Commercial success planned to expand

Funding from the EU’s Horizon 2020 programme means that the Mensia Koala neurofeedback device has been on the French market since March 2018. Mensia Technologies plan expansion into the rest of Europe by 2019-2020. Registration via the FDA for introduction into the United States is also on the schedule. “We will make it a success!” declares Dr. du Peloux.

Dr. Du Peloux goes as far as claiming that EU funding has been instrumental in making sure this key milestone of large scale clinical trial sponsorship will enable thousands of families to access the first worldwide digital therapeutics validated in Europe to treat ADHD.


Explore further:
Knowledge gaps found for non-drug therapy in peds ADHD

Tagged with:

About author

Related Articles